Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CLLS
CLLS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CLLS News
Cellectis Initiates Pivotal Trials for Lasme-cel and Eti-cel, 2026 Outlook Positive
Jan 08 2026
Globenewswire
Autolus Evaluates Cellares' Automated Platform for Manufacturing Expansion
Jan 06 2026
Newsfilter
Cellectis SA Receives Buy Rating with $9 Price Target from Clear Street
Dec 23 2025
Benzinga
Cellectis Shares Under Pressure Following Allogene Arbitration Win on Tuesday
Dec 16 2025
Benzinga
Lightwave Logic, Kyverna Therapeutics, and Other Major Stocks Decline in Tuesday's Pre-Market Trading
Dec 16 2025
Benzinga
Allogene Secures Global Control of Cema-Cel, Interim Analysis Set for 1H 2026
Dec 15 2025
Globenewswire
Allogene Secures Full Global Control of Cema-Cel Following Arbitration Ruling
Dec 15 2025
Newsfilter
Cellectis Partially Terminates License with Servier, Initiates UCART19 V1 Licensing Discussions
Dec 15 2025
Globenewswire
Cellectis Partially Terminates License Agreement with Servier, Initiates UCART19 V1 Licensing Discussions
Dec 15 2025
Newsfilter
Cellectis Reports 88% ORR for eti-cel Therapy at ASH 2025
Dec 08 2025
Globenewswire
Cellectis Presents Encouraging eti-cel Data at ASH Meeting with 88% Response Rate
Dec 08 2025
Newsfilter
Cellectis Reports Total Voting Rights of 105,406,812 as of November 30, 2025
Dec 03 2025
Globenewswire
Reasons Behind the Rise in Cellectis Stock Today
Nov 19 2025
Benzinga
Cellectis Releases Article in Nature Communications on a Non-Viral Gene Editing Method for Effective Gene Insertion in Hematopoietic Stem Cells
Nov 19 2025
Yahoo Finance
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
Nov 10 2025
NASDAQ.COM
Cellectis to Share Progress on eti-cel at ASH 2025
Nov 03 2025
Newsfilter
Show More News
